Global equities were down in April (-3.1%) with Consumer Staples, Energy and Utilities outperforming and Communication Services, Information Technology and Consumer Discretionary underperforming. The downturn was led by US equities, which underperformed broader global markets (-3.9%). The broader de-risking was in response to a more hawkish stance from the Fed and the view battling inflation remained the focus, despite growth concerns evident in the 1Q22 GDP data. European equities outperformed global markets (-0.4%) taking relief in incumbent French President Macron and his centre party remaining in power.
Asian equities outperformed the wider market (-1.2%) over the month. Chinese equities outperformed global and regional markets (-1.0%) stemming from supportive government rhetoric and indications of easing. This was despite the continued worries relating to COVID-19 restrictions and fresh regional lockdowns. Japan underperformed global and regional markets (-3.6%) as the Bank of Japan continued on a separate path of sustained easing with less of an inflationary pressure to tighten monetary policy.
Elsewhere, Brent Crude (+1.3% in USD) and Gold (-2.1%) were up and the US Dollar (+4.7%) was strong.
Key contributors included:
Key detractors included:
|30 Apr 2022||1 month||3.5||-2.8||6.2|
|30 Apr 2022||3 month||-6.8||-9.2||2.4|
|29 Apr 2022||Year to date||-4.0||-10.9||7.0|
|30 Apr 2022||1 year||-0.1||2.8||-2.9|
|30 Apr 2022||3 year p.a.||4.9||9.1||-4.1|
|30 Apr 2022||5 year p.a.||6.3||10.6||-4.2|
|30 Apr 2022||Inception p.a.||8.3||9.8||-1.5|
Past performance is not a reliable indicator of future performance. Returns are quoted in AUD and net of applicable fees, costs and taxes. All p.a. returns are annualised.
|30 Apr 2022||Average net exposure||64.9%|
|30 Apr 2022||Upside capture ratio||72|
|30 Apr 2022||Downside capture ratio||49|
|30 Apr 2022||Portfolio standard deviation||9.0%|
|30 Apr 2022||Benchmark standard deviation||10.7%|
|30 Apr 2022||Sharpe ratio||0.97|
1All metrics are based on gross of fee returns in AUD terms. The upside/downside capture ratio is the percentage of benchmark performance captured by the fundduring months that the benchmark is up/down. Standard deviation is a measure of risk with a smaller figure indicating lower return volatility. The Sharpe ratio measures returns on a risk adjusted basis with a figure > 1 indicating a higher return than the benchmark for the respective levels of return volatility.
|Global||30 Apr 2022||23 Jun 2022||POSITION||Long||0.8%|
|Global||30 Apr 2022||23 Jun 2022||POSITION||Short||2.7%|
|Global||30 Apr 2022||23 Jun 2022||POSITION||Currency||0.0%|
2Based on gross returns in AUD
|29 Apr 2022||Fund AUM||Global||AUD||$2,762m|
|29 Apr 2022||Strategy AUM||Global Long-Short||AUD||$5,048m|
|29 Apr 2022||Unit redemption price||Antipodes Global Fund (Class P)||AUD||1.7464|
|blank||Equities - Long||Other - Long||Equities - Short||Other - Short|
|Avg. weight (%)||1.6||-||-0.6||-2.1|
|Top 10 (%)||29.0||-||-14.8||-|
|Top 30 (%)||69.1||-||-22.1||-|
4Call (put) options represented as the current option value (delta adjusted exposure)
|Coterra Energy||United States||3.0|
|Frontier Communications||United States||2.9|
|Meta Platforms||United States||2.7|
6 Where possible, regions, countries and currencies classified on a look through basis
|- United Kingdom||4.0||-||4.0||0|
|- Rest Western Europe||1.0||-0.4||0.6||0|
|- China/Hong Kong||14.5||-||14.5||0|
|- Rest Developing Asia||0.5||-||0.5||0|
|Large (>$25b <$100b)||27.2||-5.2||22.0|
|Medium (>$5b <$25b)||31.2||-3.4||27.8|
1300 010 311
Antipodes Partners Limited
Level 35, 60 Margaret St
Sydney NSW 2000
Antipodes Partners Limited
6th Floor, Nova North
11 Bressenden Place
London SW1E 5BY UK
This communication is prepared by Antipodes Partners Limited (‘Antipodes’) (ABN 29 602 042 035, AFSL 481580) as the investment manager of the Antipodes Global Fund (ARSN 087 719 515) (‘the Fund’). Pinnacle Fund Services Limited (‘PFSL’) (ABN 29 082 494 362, AFSL 238371) is the product issuer of the Fund. PFSL is not licensed to provide financial product advice. PFSL is a wholly-owned subsidiary of the Pinnacle Investment Management Group Limited (‘Pinnacle’) (ABN 22 100 325 184). The Product Disclosure Statement (‘PDS’) and Target Market Determination (‘TMD’) of the Fund are available via below links. Any potential investor should consider the PDS and TMD before deciding whether to acquire, or continue to hold units in, the Fund.
Link to Product Disclosure Statement
Link to Target Market Determination
For historic TMD’s please contact Pinnacle client service Phone 1300 010 311 or Email firstname.lastname@example.org
This communication is for general information only. It is not intended as a securities recommendation or statement of opinion intended to influence a person or persons in making a decision in relation to investment. It has been prepared without taking account of any person’s objectives, financial situation or needs. Any persons relying on this information should obtain professional advice before doing so. Past performance is for illustrative purposes only and is not indicative of future performance. Options exposure represents the market downside. For put options (typically used to limit potential downside) delta-adjusted exposure is used and for call options (typically used to capture potential upside) exposure is calculated using the current option value. Unless otherwise specified, all amounts are in Australian Dollars (AUD).
Whilst Antipodes, PFSL and Pinnacle believe the information contained in this communication is reliable, no warranty is given as to its accuracy, reliability or completeness and persons relying on this information do so at their own risk. Subject to any liability which cannot be excluded under the relevant laws, Antipodes, PFSL and Pinnacle disclaim all liability to any person relying on the information contained in this communication in respect of any loss or damage (including consequential loss or damage), however caused, which may be suffered or arise directly or indirectly in respect of such information. This disclaimer extends to any entity that may distribute this communication.
Any opinions and forecasts reflect the judgment and assumptions of Antipodes and its representatives on the basis of information available as at the date of publication and may later change without notice. Any projections contained in this presentation are estimates only and may not be realised in the future.
Unauthorised use, copying, distribution, replication, posting, transmitting, publication, display, or reproduction in whole or in part of the information contained in this communication is prohibited without obtaining prior written permission from Antipodes. Pinnacle and its associates may have interests in financial products and may receive fees from companies referred to during this communication.
Zenith Disclaimer: The Zenith Investment Partners (‘Zenith’) (ABN 27 103 132 672, AFSL 226872) rating (assigned Antipodes Global Fund – November 2021) referred to in this piece is limited to “General Advice” (s766B Corporations Act 2001) for Wholesale clients only. This advice has been prepared without taking into account the objectives, financial situation or needs of any individual, including target markets of financial products, where applicable, and is subject to change at any time without prior notice. It is not a specific recommendation to purchase, sell or hold the relevant product(s). Investors should seek independent financial advice before making an investment decision and should consider the appropriateness of this advice in light of their own objectives, financial situation and needs. Investors should obtain a copy of, and consider the PDS or offer document before making any decision and refer to the full Zenith Product Assessment available on the Zenith website. Past performance is not an indication of future performance. Zenith usually charges the product issuer, fund manager or related party to conduct Product Assessments. Full details regarding Zenith’s methodology, ratings definitions and regulatory compliance are available on our Product Assessments and at Fund Research Regulatory Guidelines.
Lonsec Disclaimer: The Lonsec Rating (assigned April 2022) presented in this document is published by Lonsec Research Pty Ltd (‘Lonsec’) (ABN 11 151 658 561, AFSL 421445). The Rating is limited to “General Advice” (as defined in the Corporations Act 2001 (Cth)) and based solely on consideration of the investment merits of the financial products. Past performance information is for illustrative purposes only and is not indicative of future performance. They are not a recommendation to purchase, sell or hold Antipodes products, and you should seek independent financial advice before investing in these products. The Ratings are subject to change without notice and Lonsec assumes no obligation to update the relevant documents following publication. Lonsec receives a fee from the Fund Manager for researching the products using comprehensive and objective criteria. For further information regarding Lonsec’s Ratings methodology, please refer to our website at https://www.lonsec.com.au/fund-manager/investment-product-ratings.